Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 2 news outlets

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 11 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 2 news stories from 2 outlets.

The sobering truth about cancer immunotherapy

6 Minutes, 31 Jul 2017

Imagine being able to offer hope to people with cancers that were once thought untreatable.

Cancer immunotherapy drugs like Keytruda and Opdivo hold hope for some, but there's still a way to go

The Conversation, 31 Jul 2017

Imagine being able to offer hope to people with cancers that were once thought untreatable.